Recent news coverage includes a March 31, 2026 report on Jushi Holdings Inc.'s Q4 loss and revenue results. Broader industry and market news from July 2026 do not specifically focus on Jushi but provide context on market conditions.

• Jushi Holdings Inc. reported a Q4 loss while surpassing revenue estimates as of March 31, 2026 [N1].

Jushi benefits from recent federal regulatory changes that partially reschedule medical cannabis products to Schedule III, enabling registration with the DEA and potential tax relief under IRC Section 280E for medical cannabis operations. The company's strategic positioning to participate in newly legalized adult-use markets, such as Virginia, offers growth opportunities. Experienced leadership and a governance structure with independent directors support operational oversight and strategic execution. The company's liquidity position as of Q1 2026 provides a foundation for ongoing operations and investment in growth initiatives.

Jushi faces significant risks from the ongoing federal illegality of cannabis, which exposes it to potential criminal and civil penalties despite state-level compliance. The regulatory environment remains uncertain, with pending litigation challenging DEA rescheduling rules and unclear impacts on banking, taxation, and federal registration obligations. The company has reported substantial net losses, and operational challenges such as supply constraints, competition, and execution delays may hinder realization of market opportunities. Tax burdens under IRC Section 280E continue to affect profitability, and failure to maintain DEA compliance could result in severe penalties or loss of licenses.

Jushi's moat is primarily regulatory and operational, given the complex and evolving legal landscape of cannabis in the U.S. The company's ability to navigate federal and state regulations, including DEA registration and compliance with Schedule III requirements for medical cannabis, provides a barrier to entry. Additionally, Jushi's established licenses, production capacity, and experienced management team contribute to its competitive positioning. However, the industry faces significant risks from regulatory changes, federal enforcement, and tax burdens under IRC Section 280E, which may limit profitability and operational flexibility.

• Federal Regulatory Risk: Cannabis remains illegal under U.S. federal law as a Schedule I controlled substance, exposing Jushi to potential criminal and civil penalties despite state-level legalization and compliance.
• Taxation Under IRC Section 280E: The company is subject to tax provisions that disallow deductions for expenses related to trafficking in controlled substances, which may cause otherwise profitable operations to report losses. Partial rescheduling may provide some relief but with uncertain retroactivity and increased compliance costs.
• Operational Execution Risk: Jushi's ability to capitalize on new adult-use markets, such as Virginia, depends on successful execution of production capacity increases, inventory management, staffing, and competition handling. Execution delays or higher costs could limit benefits.
• DEA Compliance and Registration: The company must comply with DEA registration and inspection requirements for Schedule III medical cannabis operations. Failure to maintain compliance could lead to civil penalties, suspension, or revocation of registrations, impacting operations.
• Market and Competitive Risks: Increased competition, pricing pressure, and supply constraints in the cannabis industry may affect Jushi's market share and profitability.

• Jushi Holdings Inc. is a cannabis company incorporated in British Columbia, Canada, with principal executive offices in Boca Raton, Florida, USA.
• The company operates in the cannabis industry, deriving 100% of its revenues from cannabis-related activities.
• Jushi is managed by a board of five directors, four of whom are independent under Canadian Securities Administrators Guidelines.
• The CEO and Chairman is James Cacioppo, who has extensive experience in hedge funds and investment management.
• Other key executives include Louis J. Barack (President, Chief Revenue Officer, Corporate Secretary) and Michelle O. Mosier (Chief Financial Officer and Chief Accounting Officer).
• The company filed an amended 10-K for fiscal year ended December 31, 2025, and a 10-Q for the quarter ended March 31, 2026.
• As of March 31, 2026, Jushi had cash and cash equivalents of approximately $39.7 million and current assets of about $84.7 million, with current liabilities of $75.1 million, resulting in a current ratio of 1.13 and a cash ratio of 0.53.
• The company reported a net loss of approximately $68.6 million for the fiscal year ended December 31, 2025.
• Basic and diluted earnings per share for Q1 2026 were both negative $0.10 per share.
• Jushi is subject to significant regulatory risks due to cannabis being illegal under U.S. federal law, classified as a Schedule I controlled substance under the Controlled Substances Act (CSA).
• Recent federal regulatory developments include the DEA rescheduling FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III, effective April 28, 2026, with an expedited registration process for state medical cannabis licensees.
• The company is exposed to risks related to the uncertain federal regulatory environment, including potential criminal or civil penalties, tax implications under Internal Revenue Code Section 280E, and compliance with DEA registration and inspection requirements.
• Jushi is pursuing benefits from Virginia's transition to an adult-use cannabis market starting July 1, 2027, which involves operational and strategic initiatives such as increasing production capacity and managing competition.
• The company has disclosed risks related to competition, pricing pressure, operational challenges, supply constraints, and execution delays that could affect its ability to realize anticipated benefits from market opportunities.
• Jushi's board committees include Audit, Nominating and Corporate Governance, and Compensation Committees, with detailed charters and oversight responsibilities.
• The company has not disclosed detailed revenue or segment financials in the provided data but has reported losses in recent quarters and fiscal years.
• Recent news coverage includes a March 31, 2026 article reporting Jushi's Q4 loss and revenue results [N1].